LOUISVILLE, Colo., Aug. 28 /PRNewswire/ -- GlobeImmune, Inc. today announced that John Frenz, Ph.D. has joined the company as Vice President of Operations. Dr. Frenz is responsible for managing all manufacturing operations and process development for GlobeImmune.
Dr. Frenz comes to GlobeImmune with over 15 years experience in biotechnology process development and manufacturing operations. Previously, Dr. Frenz was at Genentech, Inc. where he held a variety of leadership roles, most recently Senior Director, Product Portfolio Management and prior to that Plant Manager, Biochemical Manufacturing. Dr. Frenz is an expert in protein separation and characterization, recently chairing HPLC-2006, the largest world meeting dedicated to liquid phase separation science. Dr. Frenz earned a Ph.D. in Chemical Engineering from Yale University in 1983. He also holds an M.S. in Chemical Engineering from M.I.T. and an undergraduate degree from Yale in Engineering and Applied Science.
“As a platform technology company with two product candidates already in the clinic, John’s depth of expertise will be an essential component of our plan to develop GlobeImmune into an industry-leading biotechnology company,” said Dr. Timothy C. Rodell, President & CEO of GlobeImmune. “He has a proven track record of achieving superior results in the manufacture of biologics, while coordinating the complex interactions of quality and regulatory affairs that accompany this process.”
“This is a great opportunity,” said Dr. Frenz, “to contribute to realizing the potential of GlobeImmune’s platform to improve the lives of many patients, to work with a great team, and to help make this a leading biotechnology company.”
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development, and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens(TM) for the treatment of cancer and infectious diseases. The Company’s lead infectious disease product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection, is currently in a placebo-controlled, Phase 1b human clinical trial. GI-4000, the Company’s lead oncology product, is in a randomized, placebo-controlled, multi-center Phase 2 trial for the treatment of patients with early-stage pancreas cancer.
About Tarmogens
Tarmogens are whole, heat-killed recombinant yeast that are genetically modified to express one or more disease-specific protein antigens. Tarmogens actively bind to several receptors on antigen presenting cells, including Toll-like receptors, and are avidly taken up by these cells that activate the immune system, stimulating an immune response to kill diseased cells.
For additional information, please visit the company’s website at www.globeimmune.com.
This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to the Company’s growth. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.
GlobeImmune, Inc.
CONTACT: Kirk Christoffersen, Senior Director, Corporate Development ofGlobeImmune, Inc., +1-303-625-2700, information@globeimmune.com
Web site: http://www.globeimmune.com/
